UPDATE: Jefferies Starts Vaccitech (VACC) at Buy, 'Primed Vaccine Pipeline Ready to Boost the Stock'

Jefferies analyst Peter Welford initiates coverage on Vaccitech (NASDAQ: VACC) with a Buy rating and a price target of $28.00.

The analyst comments "VACC's validated vaccine platform enables its broad pipeline of six Phase I/IIa therapies to diversify risk. We ascribe most value to VTP-200 for high-risk HPV with c.$10/share NPV, which with c.$6/share cash largely underpins the current share price. Clinical catalysts could significantly de-risk key products and potentially crystallise partnerships. AZN COVID-19 vaccine revenues could offer substantial upside optionality if our longer-term sales prove modest."

For an analyst ratings summary and ratings history on Vaccitech click here. For more ratings news on Vaccitech click here.

Shares of Vaccitech closed at $14.32 yesterday.

You May Also Be Interested In

• Clarus Securities Starts NG Energy International Corp (GASX:CN) at Buy, 'Don’t Miss the Forest for the Trees – Production Set to Triple'
• CFRA Double Upgrades Constellation Brands (STZ) to Strong Buy
• JPMorgan Downgrades ICICI Lombard (ICICIGI:IN) to Neutral